TMT India Ltd Reports FY26 Audited Financials

TMT India Limited has announced its audited financial results for the fiscal year ending March 31, 2026. The company reported a net loss of ₹0.0903 crore (₹9.03 lakh) for the fiscal year, a reduction from a net loss of ₹0.4597 crore in the previous fiscal year. Revenue from operations stood at ₹0.047 crore (₹4.70 lakh), a significant improvement from nil revenue in FY25.

Reader Takeaway: Reduced annual losses and minimal revenue, but litigation and negative equity are key concerns.

What just happened

TMT India reported its full-year audited financial results for FY2025-26. Key figures include a revenue of ₹0.047 crore and a net loss of ₹0.0903 crore. Non-current borrowings stand at ₹7.04 crore, with cash and equivalents at ₹0.0741 crore. The company's equity remains negative at -₹6.589 crore.

Why this matters

For investors, the reduced net loss is a positive sign, alongside the generation of revenue after a zero-revenue prior year. However, these are overshadowed by significant concerns. The auditor's 'Emphasis of Matter' highlights a pending litigation regarding the illegal transfer of 50,000 equity shares in M/s Sree Rayalaseema Alkalies and Allied Chemicals Ltd. Furthermore, the company continues to have negative equity, indicating accumulated losses exceeding its capital base, which raises solvency questions.

The backstory

In the previous fiscal year (FY2024-25), TMT India had reported nil revenue and a net loss of ₹0.4597 crore. The company has been carrying significant borrowings and has consistently shown negative equity.

What changes now

While the financial performance shows a slight improvement in loss reduction, the core financial and legal issues persist. The company is actively pursuing the litigation concerning the investment transfer.

Risks to watch

The primary risks for TMT India revolve around the outcome of the pending litigation, which could have significant financial and governance implications. The persistent negative equity also poses a substantial risk to the company's long-term financial health and solvency.

Auditor Remarks

The statutory auditor provided an unmodified opinion on the financial statements. However, an 'Emphasis of Matter' paragraph was included, drawing attention to the ongoing litigation concerning the illegal transfer of shares in M/s Sree Rayalaseema Alkalies and Allied Chemicals Ltd. This litigation involved 50,000 equity shares with a cost of ₹0.05 crore (₹5 lakh).

Context metrics (time-bound)

• Revenue from Operations (FY2025-26): ₹0.047 crore (₹4.70 lakh)
• Net Loss (FY2025-26): -₹0.0903 crore (-₹9.03 lakh)
• Non-current Borrowings (as of 31.03.2026): ₹7.04 crore (₹704.00 lakh)
• Equity (as of 31.03.2026): -₹6.589 crore (-₹658.90 lakh)

What to track next

Investors should closely monitor the progress and outcome of the litigation concerning the illegal transfer of shares. Updates on the company's financial health, particularly its equity position, will also be crucial.